BCM
MLTX icon

Beryl Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Beryl Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-459,243
Closed -$5.1M – 60
2022
Q1 		$5.1M Buy
+459,243
New +$4.57M 0.31% 129

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Beryl Capital Management's MLTX Position: Q2 2022 in Review

Beryl Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 459,243 shares — an estimated $5.1M sold.

Beryl Capital Management first reported a position in MLTX in Q1 2022 and held it in 1 quarter. The position peaked at $5.1M in Q1 2022. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

  • Beryl Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Beryl Capital Management sold 459,243 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $5.1M.
  • Beryl Capital Management first reported a position in MoonLake Immunotherapeutics in Q1 2022 and held it in 1 quarter.
  • Beryl Capital Management's MoonLake Immunotherapeutics position peaked at $5.1M in Q1 2022.
  • 23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on Beryl Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.